Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.